SARS-CoV-2

In his weekly clinical update, Dr. Griffin discusses global transmission of mpox, the different clades of the virus and associated pathogenesis, vaccination vs antiviral therapy against mpox and the US’s aid response for controlling the African outbreak before reviewing the recent statistics on SARS-CoV-2 infection, authorization and approval of updated COVID vaccines, the economic benefit of an annual COVID vaccine and if the first updated vaccines against XBB.1.5 were effective, where to find PEMGARDA, breakthrough infections when administering PEMGARDA, when to use convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, and how long COVID differs in children and adolescents.

In his weekly clinical update, Dr. Griffin discusses how measles in persons with secondary vaccination failure may be less infectious than in others who were never vaccinated yet infected, the recent declaration by the WHO that mpox is a public health emergency of international concern, before reviewing the recent statistics on SARS-CoV-2 infection, where to find PEMGARDA, why the use of a single monoclonal antibody against SARS-CoV-2 will result in circulation of resistant viral variants, when to use convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, public health policies and research needed for long COVID, how none of the 25 routine clinical laboratory served as a clinically useful biomarker of PASC, how symptoms of COVID-19 persist in postmenopausal women and the benefits of telemedicine for long-term patient monitoring, early diagnosis, and treatment.

In his weekly clinical update, Dr. Griffin discusses the harms of perpetuating the lab leak hypothesis and the recent ACIP recommendations for the RSV vaccine for those individuals over 60, before reviewing the recent statistics on SARS-CoV-2 infection, treatment guidelines for the different phases of COVID, including vaccines, Pemgarda, early treatment with Paxlovid, remdesivir and molnupiravir, steroids at the right time, anticoagulation support, immune modulation in some cases, and a comprehensive definition of long COVID.

In his weekly clinical update, Dr. Griffin discusses how the pandemic may have effected our trust in physicians and hospitals and if waiting longer to make strain selection for the seasonal influenza vaccine would be advantageous before reviewing the recent statistics on SARS-CoV-2 infection, how different CVODI-19 vaccines effect the cardiovascular system, if the a third of either COVID-19 mRNA vaccine is effective, where to find PEMGARDA, if convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, and the long term consequences of a SARS-CoV-2 infection on human health including incidences of diabetes, respiratory problems, hearing loss and maternal-fetal health.

In his weekly clinical update, Dr. Griffin discusses Merck’s RSV preventative monoclonal antibody Clesrovimab before reviewing the recent statistics on SARS-CoV-2 infection, if previous SARS-COV-2 infections predict the outcome of subsequent infections, if using COVID rapid diagnostic tests is cost effective, if the protein based vaccine NVX-CoV2327 elicits a durable immune response, if combination treatment of vaccine and antiviral drugs effectively protect against hospitalization, where to find PEMGARDA, what do when healthcare workers succumb to SARS-CoV-2 infection, and how COVID-19 may alter the cognitive trajectories of older patients.

In his weekly clinical update, Dr, Daniel Griffin reviews President Biden’s case of COVID, reviews recent statistics on SARS-CoV-2 infection, discusses post-acute sequelae after infection during pregnancy, the use of nirmatrelvir-ritonavir for post-exposure prophylaxis, where to find Pemgarda, effectiveness of combined nirmatrelvir-ritonavir-molnupiravir treatment, effectiveness of Ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19, effectiveness of combined nirmatrelvir-ritonavir-molnupiravir treatment in patients hospitalized with COVID-19, CDC update of Long COVID Basics page, postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras, Long COVID risk has dropped over time but remains substantial, efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID, and the interplay between diet and the gut microbiome: implications for health and disease.